Azisekho izibalo eziyinkimbinkimbi, i-EkiYou iyayiphatha! đ
Uhlelo lokusebenza lokudotshwa kwe-insulin yonke-in-one lwe:
Ibhalansi ye-glycemic engcono (1)
Inkululeko eyengeziwe ekudleni nakwezemidlalo
Ukuncipha komthwalo wengqondo wansuku zonke ohlobene nesifo sikashukela.
I-EkiYou ingumngane wabantu abanesifo sikashukela sohlobo 1 nohlobo 2 abalashwa ngepeni le-basal/bolus insulin*
â
UHLELO LONKE-LWE-ALL-IN-ONE (elakhiwe ngokuhlanganyela nabantu abangaphezu kuka-2000):
I-EkiYou ibala umthamo we-insulin ngendlela yomuntu siqu ngokusekelwe kumazinga kashukela egazini, ukudla kanye nokusebenza komzimba.
Asisekho isidingo sokwazi ukuthi ungabala kanjani ama-carbohydrate! đ Sesha noma skena ukudla kwakho ngokuchofoza okumbalwa nje usebenzisa isizindalwazi sethu sokudla sokudla okungu-+200,000, okuhlolwa futhi kubuyekezwa njalo (CIQUAL).
Faka umsebenzi wakho womzimba âčïž, ubude bawo namandla, futhi uthole isincomo somthamo we-insulin ekudleni kwakho ngokusekelwe kudatha erekhodiwe.
Yonke idatha yakho ku-Logbook đ: thola shazi yonke into oyiqophile (ushukela osegazini, ukudla, ukuvivinya umzimba, umthamo we-insulin, ukushukela).
â
KUVAKALISWE NGOKUCLINICAL:
Isekelwa ikomiti lezokwelapha elihlanganisa odokotela besifo sikashukela abangaphezu kwe-10. đ§ââïž
Ngocwaningo lwe-GLUCAL (olwenziwa eFrance), i-EkiYou uhlelo lokusebenza lokuqala olufakazelwe ngokwesayensi:
Ukuthuthukiswa kwamazinga kashukela wegazi we-post-prandial ngaphakathi kokuhlosiwe okungu-+5.75% (1)
Ukwehliswa kwamabhonasi okulungisa ngo-24% (1)
â
OKULULA FUTHI OKUNOKWENZA:
Ithuthukiswe ngodokotela abasebenza nge-Functional Insulin Therapy.
Kufinyeleleka ngaphandle kokuqeqeshwa ku-Functional Insulin Therapy.
Isevisi yangemuva kokuthengisa iyatholakala futhi onayo đŁïž
I-83% yeziguli ziyakwazi ukulungisa uhlelo ngaphandle kosizo lwangaphandle (2)
U-100% wabasebenzisi be-EkiYou bancoma uhlelo lokusebenza kwezinye iziguli (1)
U-EkiYou, umlingani wakho wokulawula okungcono kwe-glycemic. đ
I-EkiYou iyisisetshenziswa sezokwelapha esimakwe sekilasi le-IIb CE ngokuya nge-REGULATION (EU) 2017/745 futhi ihlose ukuhlinzeka ngezincomo zomthamo we-insulin. Akuhloselwe ukufaka esikhundleni sokubonisana noma ukwelashwa.
I-EkiYou ihloselwe ukusetshenziswa kuphela ngaphakathi kohlaka oluthile lwemisebenzi echazwe ngenhla. Isicelo senzelwe ukusetshenziswa kuphela abantu abadala abaneminyaka engaphezu kwe-18 ubudala futhi abanesifo sikashukela sohlobo 1 noma 2 abalashwa ngemijovo eminingi ye-insulin yansuku zonke ngephethini ye-basal-bolus.
Sicela ufunde imiyalelo yokusetshenziswa ngokucophelela ngaphambi kokusebenzisa uhlelo lwakho lokuqala noma ukuze uthole ulwazi olwengeziwe mayelana nomgomo wokusebenzisa noma ama-contraindications. Ukuze ufinyelele imiyalelo yokusetshenziswa ngefomethi ye-PDF, sicela uye kusixhumanisi esilandelayo: https://diappymed.com/ekiyou001ifu/
Uma unemibuzo yezokwelapha noma okukukhathazayo, sicela uxhumane nodokotela wakho noma isibhedlela/isikhungo sezempilo.
Noma yikuphi ukusetshenziswa okungaphandle kobubanzi bokusetshenziswa okuhlosiwe, noma abantu abangahlosiwe isicelo, akuwona umthwalo we-DiappyMed.
Idatha eqoqwe yi-DiappyMed igcinwa kumaseva edatha yezempilo agunyaziwe (i-HDS) futhi icutshungulwe ngokuvumelana ne-GDPR.
Uyayidinga Imiyalelo Yokusetshenziswa efomini lephepha?
Cela inguqulo yephepha ngokusithinta ku-: ekiyou@diappymed.com
Uma yonke imininingwane edingekayo ukuze uyithumele isinikeziwe, uzothola i-imeyili eqinisekisa isicelo sakho futhi inguqulo yephepha lakho izonikezwa kuwe phakathi kwezinsuku eziyi-7.
Imithombo:
(1) UKUSETSHENZISWA KOHLELO LOKUSEBENZA LE-DIAPPYMEDÂź LWE-CARB&BOLUS IMIPHUMELA YOKUBALA EKULAWENI OKUTHUTHUKISIWE KAYOSE NGEMVA KOKUDLA EZIGWENI EZINOHLOBO LWESIFO SIKASHUKELA ESIFUNDAZWENI SOKULAWULA OKUHLE
O. Diouri, M. Traverso, J. Place, V. Georgescu, M.C. Picot, A. Farret, E. Renard. I-Diabetes Technology & Therapeutics.Apr 2022.A-1-A-237.
http://doi.org/10.1089/dia.2022.2525.abstracts
(2) Ucwaningo Olufingqiwe Lokufaneleka ukuze lusetshenziswe ezigulini eziyi-18.
Kubuyekezwe ngo-
Mas 6, 2024